Neoadjuvant treatment of esophageal cancer: Immunosuppression following combined radiochemotherapy

摘要: Abstract Background. The biologic effects of neoadjuvant tumor therapies on the immune system cancer patients are largely unknown. Immune deviations may be particularly detrimental if they occur in conjunction with postoperative immunosuppression. combined radiochemotherapy (RCTx) T cell functions squamous carcinoma esophagus were investigated. Methods. proliferation was stimulated by incubation peripheral blood mononuclear cells bacterial superantigens or exposure enriched to presented B lymphoma cells. Cytokine production induced cross-linking CD3 and CD28 secretion interleukin (IL)-2, IL-4, IL-10, interferon-γ measured enzyme-linked immunosorbent assay. expression human leukocyte antigen-DR (HLA-DR) molecules determined flow cytometry. Results. lymphocytes from having undergone RCTx exhibited a significantly reduced proliferative response following stimulation 3 independent superantigens. antigen presenting capacity patient's not diminished RCTx. HLA-DR increased Conclusions. results suppression lymphocyte functions. defects after linked an impaired surveillance higher risk surgical complications associated esophagectomy. (Surgery 2002;132:495-501.)